康哲藥業(00867.HK)擬收購上海旭俐醫療器械100%股權 以豐富醫美領域產品矩陣
格隆匯12月8日丨康哲藥業(00867.HK)發佈公吿，於2021年12月8日，集團通過公司附屬公司-皮膚醫美業務公司（康哲美麗）向若干獨立第三方賣方收購一家醫學美容專業公司上海旭俐醫療器械有限公司（目標公司）的100%股權。收購事項完成後，目標公司成為公司的附屬公司，其業績及資產與負債將合併入集團的賬目內。
目標公司專注於醫美產品領域，紮根醫美行業中上游產業鏈，集研發、生產、銷售、定製代工於一體，旨在為中國愛美人士提供全球高品質的醫美產品、設備及服務等。目標公司主要產品為韓國進口玻尿酸-注射用修飾透明質酸鈉凝膠MONALISA LidocaineFiller（Vmonalisa莫娜麗莎）（玻尿酸產品），目標公司是玻尿酸產品在中國大陸的獨家總經銷商。目標公司創始人團隊擁有10年以上醫美行業從業經驗，對醫美行業有深刻理解並積累了大量資源；其銷售團隊具有豐富的醫美產品市場運作及銷售推廣經驗。目標公司已建立了覆蓋中國大陸知名醫美機構的銷售網絡，覆蓋全國逾800家醫療美容機構。
收購事項符合集團向醫美領域持續發展的戰略。目標公司玻尿酸產品是輕醫美（非手術類醫美）領域的主流及核心產品之一，可豐富集團醫美領域的產品矩陣，同時為中國愛美人士提供時尚、高性價比、韓國進口的輕奢玻尿酸產品，以滿足不同求美者對美的需求。
收購事項也將為集團帶來優秀的醫美業務管理及銷售推廣團隊，以及覆蓋廣泛的醫美銷售渠道資源，助力集團醫美銷售推廣能力及渠道拓展，不斷鞏固和提升集團在醫美領域的綜合競爭力，打造良好的市場和品牌形象，打造全球醫美產品的業務平台，為持續收購及引進醫美產品夯實基礎。
隨着中國消費者對美的需求持續增加，消費能力和消費意願不斷提升，集團將持續利用全球資源，將國際一流的、技術先進的醫美產品引入中國，形成以輕醫美、醫美器械、皮膚學級護膚品三大醫美產品矩陣，並依託日益成熟的醫美銷售推廣體系高效推進、高速發展。同時集團將持續擴充皮膚專科領域產品管線以及銷售推廣體系建設，將康哲美麗打造為中國領先的皮膚醫美健康管理公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
